Coumarin–furo[2,3- d ]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies
RSC Medicinal Chemistry · 2024 · 15 (5) · 1565-1577
DOI: 10.1039/d3md00668a ↗Kurz gefasst
Fachartikel in der Zeitschrift RSC Medicinal Chemistry, 2024. Verfasst von Tianshuai Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hubei University of Medicine Shiyan 442000 Hubei China wtshuaiynn@163.com. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Hubei Provincial Department of Education.
Abstract (Originalsprache)
Coupling a furopyrimidone scaffold with coumarin through a hydrazide linker can effectively improve their synergistic anticancer activity targeting HepG2.
Autor:innen und Institutionen
- School of Pharmacy, Hubei University of Medicine Shiyan 442000 Hubei China wtshuaiynn@163.com.
- Hubei Key Lab of Wudang Local Chinese Medicine Research, School of Pharmacy, Hubei University of Medicine Shiyan 442000 Hubei China.
ORCID-Profile: Tianshuai Wang
Förderung
- Hubei Provincial Department of Education
Zitieren
APA
Wang, T., Gao, Y., Wu, F., Luo, L., Ma, J., & Hu, Y. (2024). Coumarin–furo[2,3- d ]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies. RSC Medicinal Chemistry, 15(5), 1565-1577. https://doi.org/10.1039/d3md00668a
Vancouver
Wang T, Gao Y, Wu F, Luo L, Ma J, Hu Y. Coumarin–furo[2,3- d ]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies. RSC Medicinal Chemistry. 2024;15(5):1565-1577. doi:10.1039/d3md00668a
BibTeX
@article{Wang2024,
author = {Wang, Tianshuai and Gao, Yumeng and Wu, Fengxu and Luo, Lun and Ma, Junkai and Hu, Yanggen},
title = {Coumarin–furo[2,3- d ]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies},
journal = {RSC Medicinal Chemistry},
year = {2024},
volume = {15},
number = {5},
pages = {1565--1577},
doi = {10.1039/d3md00668a}
}
EUVIMED